Sage Therapeutics’ stock drops 49% after FDA approves zuranolone for postpartum depression but not for major depressive disorder
August 07, 2023 at 10:46 AM EDT
The good news on postpartum depression was offset by disappointment about major depressive disorder, which would be a far greater opportunity.
